Orthopedic devices maker Orthofix makes big strides in its profit margin expansion program, but suffers setbacks in sales due to obstacles in international markets.
Medical device maker Orthofix (NSDQ:OFIX) posted huge growth for its bottom line in both the 4th quarter and full year of 2012, but reported sliding sales and projected slow growth for the year ahead.
The Lewisville, Texas-based company posted profit of $20.5 million, or $1.04 per diluted share, on sales of $112 million during the 3 months ended Dec. 31, 2012.
That represents a 65.5% spike in profit but a 9% decrease in sales compared with the same period in 2011, when the company posted $12.4 million in earnings, or 66¢ EPS, on sales of $123.1 million.
Adjusted for 1-time expenses, 4th-quarter earnings amounted to 81¢ per share, right in line with analysts' expectations.
Orthofix suffered hits to both its total spine and orthopedic divisions, according to the earnings release. Orthopedics were hit particularly hard, with 4th-quarter sales sinking 18% compared with the same time in 2011.
"This decrease was primarily due to regulatory and macroeconomic conditions in certain international markets, which included mandatory price reductions for public hospitals in Italy, cancellation of reimbursement by the government on Physio-Stim in France, and a delay of surgeries by government hospitals and insurance providers," according to the report.
A federal jury in Texas clears Johnson & Johnson's DePuy Pinnacle hip implant in the 1st...
Edwards Lifesciences reports 3rd-quarter sales and earnings growth in excess of 20% and raises its...
A federal jury in Texas reportedly clears Johnson & Johnson's DePuy Pinnacle hip implant in the...
Federal auditors say the FDA needs to ramp up its cybersecurity efforts in order to deter hackers.